Otler tuzumab more than a TRU(E) toddler in CLL?

Blood

Volumn 123, Issue 9, 2014, Pages 1282-1284

  Wendtner, Clemens Martin ^a,b  

^a Klinikum Schwabing   (Germany)

^b UNIVERSITY OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

OTLERTUZUMAB; ANTINEOPLASTIC AGENT; HYBRID PROTEIN; IMMUNOGLOBULIN G;

CANCER IMMUNOTHERAPY; CANCER RISK; CHILL; CHRONIC LYMPHATIC LEUKEMIA; DIARRHEA; DRUG DOSE ESCALATION; DRUG SAFETY; FATIGUE; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MONOTHERAPY; NAUSEA; NEUTROPENIA; NOTE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RECURRENCE RISK; SIGNAL TRANSDUCTION; THROMBOCYTOPENIA; TREATMENT RESPONSE; FEMALE; MALE;

ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; IMMUNOGLOBULIN G; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; RECOMBINANT FUSION PROTEINS;

EID: 84897897082     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-01-548560     Document Type: Note

References (10)

1. Byrd JC, Pagel JM, Awan FT, et al. A phase 1 study evaluating the safety and tolerability of otlertuzumab, an anti-CD37 mono-specific ADAPTIR therapeutic protein in chronic lymphocytic leukemia. Blood. 2014;123(9):1302-1308.
2. Krause G, Patz M, Isaeva P, et al. Action of novel CD37 antibodies on chronic lymphocytic leukemia cells. Leukemia. 2012;26(3):546-549.
3. Robak T, Robak P, Smolewski P. TRU-016, a humanized anti-CD37 IgG fusion protein for the potential treatment of B-cell malignancies. Curr Opin Investig Drugs. 2009;10(12):1383-1390.
4. Hallek M, Fischer K, Fingerle-Rowson G, et al International Group of Investigators; German Chronic Lymphocytic Leukaemia Study Group. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet. 2010;376(9747):1164-1174.
5. Goede V, Fischer K, Busch R, et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions [published online ahead of print January 8, 2014]. N Engl J Med.
6. Wiestner A. Emerging role of kinase-targeted strategies in chronic lymphocytic leukemia. Hematology (Am Soc Hematol Educ Program). 2012;2012:88-96.
7. Byrd JC, Furman RR, Coutre SE, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013;369(1):32-42.
8. Souers AJ, Leverson JD, Boghaert ER, et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med. 2013;19(2):202-208.
9. Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med. 2011;365(8):725-733.
10. Lapalombella R, Yeh Y-Y, Wang L, et al. Tetraspanin CD37 directly mediates transduction of survival and apoptotic signals. Cancer Cell. 2012;21(5):694-708.